Zobrazeno 1 - 10
of 746
pro vyhledávání: '"J. A. Burguera"'
Autor:
F. Winter
Publikováno v:
Angewandte Chemie. 102:593-594
Autor:
A.R. Morrisson
Publikováno v:
Talanta. 38:813
Autor:
F. Winter
Publikováno v:
Angewandte Chemie International Edition in English. 29:819-819
Autor:
M. Stoeppler
Publikováno v:
Nachrichten aus Chemie, Technik und Laboratorium. 38:254-254
Autor:
Stoeppler, M.
Publikováno v:
Nachrichten Aus Chemie Technik und Laboratorium; February 1990, Vol. 38 Issue: 2 p254-254, 1p
Autor:
Mota, Wanessa J. S.1 (AUTHOR), Guedes, Beatriz N.2 (AUTHOR), Jain, Sona3 (AUTHOR), Cardoso, Juliana C.1 (AUTHOR), Severino, Patricia1 (AUTHOR) patricia_severino@itp.org.br, Souto, Eliana B.2,4 (AUTHOR) eliana.souto@ucd.ie
Publikováno v:
Discover Public Health. 10/7/2024, Vol. 21 Issue 1, p1-12. 12p.
Publikováno v:
Revista Española de Medicina Nuclear. 21:281-285
We have studied three women (66,72 and 72 years) with Parkinson's disease of 11, 6 and 21 years of evolution and drug-resistant severe depressive episodes treated with electroconvulsive therapy (ECT). We have performed a brain SPECT (99mTc-HMPAO) bef
Autor:
J, Kulisevsky, M R, Luquin, J M, Arbelo, J A, Burguera, F, Carrillo, A, Castro, J, Chacón, P J, García-Ruiz, E, Lezcano, P, Mir, J C, Martinez-Castrillo, I, Martínez-Torres, V, Puente, A, Sesar, F, Valldeoriola-Serra, R, Yañez
Publikováno v:
Neurologia (Barcelona, Spain). 28(9)
Many patients who have had Parkinson's disease (PD) for several years will present severe motor fluctuations and dyskinesias which require more aggressive therapies. The different approaches which are now available include deep brain stimulation of t
Autor:
J, Kulisevsky, M R, Luquin, J M, Arbelo, J A, Burguera, F, Carrillo, A, Castro, J, Chacón, P J, García-Ruiz, E, Lezcano, P, Mir, J C, Martinez-Castrillo, I, Martínez-Torres, V, Puente, A, Sesar, F, Valldeoriola-Serra, R, Yañez
Publikováno v:
Neurologia (Barcelona, Spain). 28(8)
A large percentage of patients with Parkinson's disease (PD) develop motor fluctuations, dyskinesias, and severe non-motor symptoms within 3 to 5 years of starting dopaminergic therapy, and these motor complications are refractory to treatment. Sever
Publikováno v:
Fresenius' Journal of Analytical Chemistry. 353:133-136